Amvisc Plus

Drug Overview

In the highly technical field of OPHTHALMOLOGY, the success of intricate microsurgical procedures depends heavily on the tools used to stabilize the internal environment of the eye. Amvisc Plus is a premier medical device belonging to the VISCOELASTIC AGENT drug class. It is a sterile, non-pyrogenic, high-molecular-weight solution of sodium hyaluronate. Unlike a traditional BIOLOGIC used for systemic disease or a VEGF INHIBITOR used for chronic retinal conditions, Amvisc Plus serves as a specialized “Ophthalmic Viscosurgical Device” (OVD).

For patients undergoing surgery for vision-threatening conditions such as cataracts, this agent provides a “liquid cushion” that protects the eye’s delicate internal structures. Its primary role is to maintain the shape of the eye and shield sensitive cell layers from mechanical trauma. By providing a clear and stable surgical field, it enables surgeons to perform complex maneuvers with a high degree of precision, ultimately preserving the patient’s visual potential.

• Generic Name: Sodium Hyaluronate
• US Brand Names: Amvisc Plus
• Drug Class: VISCOELASTIC AGENT (Ophthalmic Viscosurgical Device)
• Route of Administration: Intraocular Injection (instilled directly into the eye during surgery)
• FDA Approval Status: Fully FDA-approved as a surgical aid in anterior and posterior segment ophthalmic procedures.

What Is It and How Does It Work? (Mechanism of Action)

Amvisc Plus is composed of a highly purified fraction of sodium hyaluronate, a naturally occurring polysaccharide found in the vitreous humor of the eye and the synovial fluid of joints. To understand its role in OPHTHALMOLOGY, one must look at its unique rheological properties—specifically its “visco-cohesive” nature.

At the molecular and physiological level, Amvisc Plus acts as a space-occupying TARGETED THERAPY during surgery. When the eye is opened during a procedure, the natural internal pressure and fluids (aqueous humor) can escape, potentially causing the eye to lose its shape or collapse. Amvisc Plus works through three primary mechanisms:

1. Space Maintenance: Due to its high viscosity and cohesive properties, it creates a stable, pressurized volume within the anterior chamber. This keeps the cornea lifted away from the iris and lens, providing the surgeon with a clear “surgical field” and room to manipulate instruments safely.
2. Endothelial Protection: The innermost layer of the cornea, the endothelium, consists of cells that do not regenerate. Contact with surgical instruments or ultrasound energy (phacoemulsification) can cause permanent cell death, leading to corneal clouding. Amvisc Plus coats these cells with a protective molecular shield, absorbing mechanical energy and preventing physical friction.
3. Tissue Manipulation: It possesses high “cohesivity,” meaning the molecules stick together in a mass. This allows the surgeon to gently push back the iris or a detached retina, helping to reposition tissues without causing tears or bleeding.

Because it is cohesive, Amvisc Plus is easily and thoroughly removed by the surgeon at the end of the procedure through irrigation and aspiration, which is critical for maintaining healthy intraocular pressure post-operatively.

FDA-Approved Clinical Indications

Primary Indication: Joint Lubrication and Surgical Protection

While hyaluronate is used for joint lubrication in orthopedics, its primary FDA-approved use in OPHTHALMOLOGY is as a surgical aid and protective agent during cataract extraction and intraocular lens (IOL) implantation. It provides the necessary lubrication and mechanical protection required for the safe insertion of synthetic lenses and the manipulation of ocular tissues.

Other Approved & Off-Label Uses

Beyond cataract surgery, Amvisc Plus is utilized across various surgical sub-specialties in OPHTHALMOLOGY:

• Corneal Transplant Surgery: Used to maintain the anterior chamber and protect the donor graft during keratoplasty.
• Glaucoma Filtering Surgery: Utilized during trabeculectomies to prevent the collapse of the eye and manage the formation of the drainage bleb.
• Retinal Reattachment Surgery: Aids in the manipulation of a detached retina and helps stabilize the posterior segment during vitrectomy.
• Ocular Trauma Repair: Helps reform the eye after penetrating injuries, allowing for the stabilization of the blood-retinal barrier during reconstruction.

Primary Ophthalmology Indications Summary:

• Preserving Visual Acuity: By preventing corneal endothelial cell loss and mechanical trauma.
• Managing Intraocular Pressure: By ensuring the drainage structures (trabecular meshwork) are not crushed during surgery.
• Stabilizing the Blood-Retinal Barrier: By minimizing surgical inflammation and trauma in the posterior segment.

Dosage and Administration Protocols

The administration of Amvisc Plus is determined by the volume required to fill the surgical space. It is instilled via a sterile cannula directly into the eye under microscopic visualization. Unlike chronic drops, there is no “loading” or “maintenance” phase; it is a single-event surgical application.

Indication	Standard Dose	Frequency
Cataract Surgery	0.2 mL to 0.6 mL (variable)	Single intraoperative application.
IOL Implantation	Small volume to coat the lens	Single intraoperative application.
Corneal Transplant	0.5 mL to 1.0 mL (variable)	Single intraoperative application.

Specific Instructions:

• Removal: It is a mandatory clinical protocol that the VISCOELASTIC AGENT be thoroughly removed from the eye via irrigation and aspiration at the conclusion of the surgery to prevent pressure spikes.
• Storage: Amvisc Plus should be refrigerated, but must be allowed to reach room temperature (20 to 30 minutes) before use to ensure the correct viscosity for the surgeon.
• Handling: The agent is supplied in a disposable syringe to maintain a PRESERVATIVE-FREE environment and ensure sterility.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical study data from 2020 to 2026 confirm that Amvisc Plus remains a gold standard in viscosurgical protection. Efficacy in this category is measured by the preservation of delicate ocular structures rather than a change in Best Corrected Visual Acuity (BCVA) letters directly, as the surgery itself is the primary driver of vision gain.

Precise Numerical Data:

• Endothelial Cell Loss: In comparative clinical trials, the use of Amvisc Plus during cataract surgery limited endothelial cell loss to less than 6%, compared to losses exceeding 20% in procedures where no viscoelastic was used.
• Space Maintenance: Research confirms that high-molecular-weight hyaluronate maintains 98% of the anterior chamber depth during the critical phase of intraocular lens insertion.
• IOP Management: While OVDs can cause temporary pressure spikes, studies show that with proper removal protocols, Intraocular Pressure (IOP) typically returns to within 3 mmHg of baseline within 24 hours post-surgery.

By protecting the cornea, Amvisc Plus ensures that the patient achieves their maximum potential visual outcome once the cloudy lens is removed.

Safety Profile and Side Effects

Black Box Warning: There is NO Black Box Warning for Amvisc Plus.

Common Side Effects (>10%)

Because Amvisc Plus is used intraoperatively, side effects are usually related to its presence in the early post-operative period:

• Transient Post-operative IOP Spike: This is the most common issue. If any agent remains in the eye, it can “clog” the drainage angle, leading to a temporary increase in eye pressure.
• Mild Post-operative Inflammation: A normal biological response to surgical intervention.

Serious Adverse Events

• Secondary Glaucoma: If a post-operative pressure spike is severe and unmanaged, it can damage the optic nerve.
• Endophthalmitis: A rare but severe intraocular infection associated with any invasive surgery.
• Corneal Edema: Usually temporary, but can occur if the viscoelastic did not sufficiently protect the endothelium or was not removed.
• Cataract Progression: (Not applicable as it is used during cataract removal, but mechanical trauma can occur).

Management Strategies: Surgeons utilize high-flow irrigation to “wash out” the agent. Post-operative monitoring for “floaters,” sudden pain, or light sensitivity is essential. If a pressure spike is detected, topical pressure-lowering drops are prescribed as a temporary measure.

Research Areas

Direct Clinical Connections

Active research (2024-2026) is investigating the interaction between sodium hyaluronate and the health of the retinal pigment epithelium (RPE) during complex vitrectomies. There is interest in whether the molecular coating properties of Amvisc Plus can provide neuroprotection to the optic nerve head during high-pressure phases of surgery.

Generalization

The development of “Visco-adaptive” devices is a major research area in 2026. These devices change their properties based on the flow rate of surgical instruments. Research is also ongoing into sustained-release intraocular implants that can be delivered alongside the viscoelastic to manage inflammation for weeks after the surgery.

Severe Disease & Surgical Integration

Research is evaluating Amvisc Plus as a vital adjunct in end-stage glaucoma surgeries. Maintaining the anterior chamber during the placement of a glaucoma drainage device, it helps prevent blindness caused by flat chambers and corneal-lenticular contact.

Disclaimer: These studies regarding RPE interaction and visco-adaptive delivery are currently in the preclinical phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Establish Baseline Visual Acuity and Tonometry (IOP measurement).
• Ocular Imaging: Optical Coherence Tomography (OCT) is used to check for macular health before surgery.
• Specimen Testing: Specular Microscopy counts the endothelial cells. A low count requires a higher volume of Amvisc Plus for protection.
• Screening: Review history for previous ocular surgeries, herpes simplex keratitis, or allergies to sodium hyaluronate.

Monitoring and Precautions

• Vigilance: Monitoring for “rebound” inflammation or sudden spikes in IOP in the first 24 hours.
• Lifestyle: Advise UV protection (sunglasses) and strict eyelid hygiene (lid scrubs) post-operatively to prevent infection.
• Dietary: The AREDS2 formula may be recommended if the patient has underlying macular degeneration to support retinal health during recovery.

Do’s and Don’ts:

• DO follow all post-operative drop schedules to manage pressure.
• DO wear your eye shield as directed by the surgeon.
• DON’T rub the eye after surgery, as this can displace the incision.
• DON’T perform heavy lifting or bending, which can increase eye pressure.

Legal Disclaimer

This guide is for informational purposes only and does not replace the advice of your surgeon. Amvisc Plus is a medical device used only in a surgical setting. Any concerns regarding surgical risks should be discussed directly with your ophthalmologist. Information is accurate as of early 2026.